# Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD

**Authors:** Mia Jensen, Steffen F. Nielsen, Steffen Thiel, Søren W.K. Hansen, Yaseelan Palarasah, Per Svenningsen, Jesper N. Bech, Frank H. Mose, Boye L. Jensen

PMC · DOI: 10.1016/j.ekir.2024.11.014 · Kidney International Reports · 2024-11-18

## Full-text entities

- **Genes:** SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}
- **Diseases:** CKD (MESH:D012080), Diabetes (MESH:D003920)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11843100/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11843100/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC11843100/full.md

---
Source: https://tomesphere.com/paper/PMC11843100